GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? [Yahoo! Finance]
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]
GH Research (GHRS) was given a new $34.00 price target by Guggenheim.
GH Research (GHRS) had its price target raised by Citizens Jmp from $39.00 to $42.00. They now have a "market outperform" rating on the stock.